Business Context and Reporting Period
Company: Biogen Idec Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Overview: Biogen Idec is a global biotechnology company focused on oncology, neurology, and immunology. The company's portfolio includes five primary products: AVONEX (multiple sclerosis), RITUXAN (non-Hodgkin's lymphoma and rheumatoid arthritis), TYSABRI (multiple sclerosis), ZEVALIN (non-Hodgkin's lymphoma), and AMEVIVE (psoriasis). The reporting period was significantly impacted by the voluntary suspension of TYSABRI in February 2005 due to safety concerns regarding progressive multifocal leukoencephalopathy (PML) and the implementation of a comprehensive strategic plan to reduce operating expenses and divest non-core assets.
Key Financial Metrics
| Metric | 2005 | 2004 |
|---|---|---|
| Total Revenues | $2,422.5 million | $2,211.6 million |
| Net Income | $160.7 million | $25.1 million |
| Diluted EPS | $0.47 | $0.07 |
| Operating Cash Flow | $889.5 million | $728.0 million |
| Cash, Cash Equivalents & Marketable Securities | $2,055.1 million | $2,167.6 million |
| Total Assets | $8,366.9 million | $9,165.8 million |
| Long-Term Debt (Notes Payable) | $43.4 million | $101.9 million |
Revenue Breakdown (2005):
- Product Sales: $1,617.0 million (AVONEX: $1.54 billion; AMEVIVE: $48.5 million; ZEVALIN: $20.8 million; TYSABRI: $4.7 million).
- Unconsolidated Joint Business (RITUXAN): $708.9 million.
- Royalties: $93.2 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 9.5% to $2.42 billion, driven primarily by growth in AVONEX sales ($1.54 billion vs. $1.42 billion in 2004) and increased RITUXAN copromotion profits ($513.8 million vs. $457.0 million).
- Profitability Surge: Net income increased significantly to $160.7 million from $25.1 million in 2004. This improvement was aided by the absence of the $823 million in-process research and development (IPR&D) charge recorded in 2003 and improved gross margins on product sales.
- Debt Reduction: The company repurchased approximately 99.2% of its senior notes due in 2032 in May 2005 for $746.4 million, significantly reducing long-term debt obligations.
- Asset Sales: The company sold its NIMO manufacturing facility in Oceanside, California, to Genentech for $408.1 million, resulting in a recorded loss of $83.5 million.
- Restructuring: Implemented a strategic plan reducing the workforce by approximately 17% (650 positions) and incurring $31.4 million in restructuring charges.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management is focused on a strategic plan to enhance economic flexibility and commit capital to external R&D. The company expects to continue investing in the development of RITUXAN for new indications (RA, CLL) and the potential re-launch of TYSABRI.
Key Risks and Contingencies
- TYSABRI Safety Issues: The voluntary suspension of TYSABRI due to PML cases remains the most significant risk. While the FDA removed the clinical trial hold in February 2006 and granted Priority Review for the sBLA, the future commercial availability is uncertain. The company wrote down $19.1 million of TYSABRI inventory in 2004 and expensed $23.2 million of manufacturing costs in 2005 due to uncertainty.
- Product Liability Litigation: The company faces multiple lawsuits related to TYSABRI, including a wrongful death claim and class actions alleging securities fraud regarding the suspension. An SEC investigation into the suspension is ongoing.
- RITUXAN Off-Label Promotion: A False Claims Act lawsuit alleges illegal off-label promotion of RITUXAN for rheumatoid arthritis prior to FDA approval. The FDA approved the RA indication in February 2006.
- Divestiture of AMEVIVE: The company is seeking to divest AMEVIVE. Inventory was written down by $31.8 million to net realizable value in 2005.
Unusual Items
- Facility Impairments: Recorded $118.1 million in facility impairments and loss on sale, primarily due to the sale of the NIMO facility and write-downs of the NICO facility.
- Inventory Write-downs: Total inventory write-downs to net realizable value were $84.0 million, including significant charges for TYSABRI and AMEVIVE.
Important Facts for Investor Verification
- TYSABRI Regulatory Status: Verify the outcome of the FDA Advisory Committee meeting scheduled for March 7, 2006, and the subsequent decision on commercial re-launch.
- Inventory Valuation: Confirm the remaining carrying value of TYSABRI and AMEVIVE inventory and the likelihood of future write-downs if divestiture or re-launch plans change.
- Litigation Exposure: Monitor the status of the SEC investigation and the various TYSABRI-related product liability and securities class action lawsuits.
- RITUXAN Profit Sharing: Understand the impact of the Genentech collaboration agreement on future profit-sharing percentages as new anti-CD20 products are approved.
- Debt Obligations: Verify the remaining terms and conversion options for the subordinated notes due in 2019 ($75.4 million remaining).